Invivyd Inc
Company Profile
Business description
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Contact
1601 Trapelo Road
Suite 178
WalthamMA02451
USAT: +1 781 819-0080
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
100
Stocks News & Analysis
stocks
ASX healthcare giant remains well positioned despite share slump
stocks
Australian bank remains overvalued despite strong result
stocks
Chart of the Week: Soft earnings growth outlook for Australian banks
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.80 | 41.30 | -0.44% |
| CAC 40 | 8,403.89 | 90.65 | 1.09% |
| DAX 40 | 25,157.55 | 301.40 | 1.21% |
| Dow JONES (US) | 49,451.98 | 669.42 | -1.34% |
| FTSE 100 | 10,463.00 | 9.11 | -0.09% |
| HKSE | 27,032.54 | 233.84 | -0.86% |
| NASDAQ | 22,597.15 | 469.32 | -2.03% |
| Nikkei 225 | 57,639.84 | 10.70 | -0.02% |
| NZX 50 Index | 13,489.17 | 42.31 | -0.31% |
| S&P 500 | 6,832.76 | 108.71 | -1.57% |
| S&P/ASX 200 | 9,043.50 | 18.50 | -0.20% |
| SSE Composite Index | 4,134.02 | 2.03 | 0.05% |